![](https://webarchive.library.unt.edu/eot2008/20090117110948im_/http://www.cdc.gov/ncidod/eid/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090117110948im_/http://www.cdc.gov/ncidod/eid/images/spacer.gif) |
Letter
Community Transmission of
Extended-Spectrum ß-Lactamase
Beatriz Mirelis,*† Ferran Navarro,*† Elisenda Miró,* Raul Jesús Mesa,*
Pere Coll,*† and Guillem Prats*†
*Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; and †Universitat
Autònoma de Barcelona, Barcelona, Spain
Suggested citation for this article: Mirelis
B, Navarro F, Miró E, Mesa RJ, Coll P, Prats G. Community transmission
of extended-spectrum ß-lactamase. Emerg Infect Dis [serial online]
2003 Aug [date cited]. Available from: URL: http://www.cdc.gov/ncidod/EID/vol9no8/03-0094.htm
To the Editor: The spread of multiresistant gram-negative bacteria
in the general population is a problem of paramount importance, but the
responsible mechanisms are poorly understood. Several studies have focused
on ß-lactam resistance in Enterobacteriaceae isolated from
stools in healthy people, but they did not specifically investigate the
extended-spectrum ß-lactamases (ESBL). Furthermore, none of these
studies detected ESBL in the evaluated population (1,2).
We performed three survey studies to determine the incidence of Enterobacteriaceae
strains producing ESBLs in the stools of outpatients attending our hospital.
The first study was performed during a 4-month period (February–May 2001),
the second during a 3 month-period (April–June 2002), and the third during
1 month (October 2002).
Stool samples were spread onto plates of MacConkey agar containing 2
mg/L of cefotaxime. A colony of each distinct morphotype was analyzed
further. Species were identified according to conventional methods (3).
The susceptibility to ß-lactam antibiotics was determined by the
disk-diffusion test, following recommendations of the National Committee
for Clinical Laboratory Standards (4,5). The interpretative
reading of the antibiogram was performed according to standard guidelines
(4–6). The MICs of cefotaxime and ceftazidime, with and
without clavulanic acid, were later determined by E test (AB Biodisk,
Solna, Sweden). Strains producing ESBL were defined as strains showing
synergism between amoxicillin-clavulanic acid and cefotaxime, ceftazidime,
cefepime, or aztreonam (4,5).
All strains suspected of carrying a resistance pattern compatible with
hyperproduction of the chromosomal enzymes, as well as resistant strains
without synergy, were disregarded. During the first period, 15 (2.1%)
of 707 outpatients were carriers of Escherichia coli (14 patients)
or Proteus mirabilis (1 patient) with ESBL. This percentage increased
during the second period, when 17 (3.8%) of 454 outpatients were carriers
of E. coli with ESBL, and again in the third period, when 12 (7.5%)
of 160 were carriers of E. coli (11 patients) or Enterobacter
cloacae (1 patient) with ESBL. Characterization of the different ESBL
isolated during the three study periods is in process. Although Klebsiella
pneumoniae carrying ESBL has been detected in our hospital (7),
as well as in other hospitals in Barcelona (8), no ESBL-producing
K. pneumoniae strains were identified in this survey.
Although we did not disregard either the patients’ previous treatment
with antibiotics or previous hospitalization, these patients came to the
hospital from the community carrying strains that express ESBL. Moreover,
during these three periods we observed a significant increase in the frequency
of ESBL carriers (from 2.1% to 7.5%; p<0.005). These data suggest that
the community could be a reservoir for these enzymes, as occurs with other
microorganisms (9–11). Many questions remain unanswered
regarding the diffusion mechanisms of this resistance in the community.
Confirmation of community-based transmission of ESBL would indicate a
need for heightened vigilance and further studies to determine the reservoirs
and vehicles for dissemination of ESBL within the community.
References
- Briñas L, Zarazaga M, Saenz Y, Ruiz-Larrea F, Torres
C. ß-lactamases
in ampicillin-resistant Escherichia coli isolates from foods,
humans, and healthy animals. Antimicrob Agents Chemother 2002;46:3156–63.
- Österblad M, Hakanen A, Manninen R, Leistevuo T, Peltonen R, Meurman
O, et al. A
between-species comparison of antimicrobial resistance in enterobacteria
in fecal flora. Antimicrob Agents Chemother 2000;44:1479–84.
- Murray P, Baron E, Pfaller M, Tenover F, Yolken R. Manual of clinical
microbiology. 7th ed. Washington: American Society for Microbiology;
1999.
- National Committee for Clinical Laboratory Standards. Performance
standards for antimicrobial disk susceptibility test. Document M2-A7.
7th ed. Wayne (PA): The Committee; 2000.
- National Committee for Clinical Laboratory Standards. Supplemental
tables: disk diffusion. Document M100-S10. Wayne (PA): The Committee;
2000.
- Livermore DM. ß-lactamases
in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557–84.
- Sabaté M, Miró E, Navarro F, Vergés C, Aliaga R, Mirelis B, et al.
Beta-lactamases
involved in resistance to broad-spectrum cephalosporins in Escherichia
coli and Klebsiella spp. clinical isolates collected between
1994 and 1996, in Barcelona (Spain). J Antimicrob Chemother 2002;49:989–97.
- Hernández JR, Pascual A, Cantón R, Martínez-Martínez L, Grupo de Estudio
de Infección Hospitalaria (GEIH). Escherichia coli y Klebsiella
pneumoniae productores de betalactamasas de espectro extendido en
hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol
Clin 2003;21:77–82.
- Chambers HF. The
changing epidemiology of Staphylococcus aureus? Emerg Infect
Dis 2001;8:178–82.
- Garau J, Xercavins M, Rodríguez-Carballeira M, Gómez-Vera JR, Coll
I, Vidal D, et al. Emergence
and dissemination of quinolone-resistant Escherichia coli in
the community. Antimicrob Agents Chemother 1999;43:2736–41.
- Tomasz A. New
faces of an old pathogen: emergence and spread of multidrug-resistant
Streptococcus pneumoniae. Am J Med 1999;107:55S–62S.
|